Trade Gyre Therapeutics Inc - GYRE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0868 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 10.7366 |
| Open | 10.7166 |
| 1-Year Change | -53.89% |
| Day's Range | 10.5366 - 10.8966 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 10.8966 | 0.2800 | 2.64% | 10.6166 | 10.8966 | 10.5366 |
| Jan 16, 2025 | 10.7366 | -0.2300 | -2.10% | 10.9666 | 11.0166 | 10.5166 |
| Jan 15, 2025 | 10.8866 | 0.4100 | 3.91% | 10.4766 | 10.9766 | 10.4766 |
| Jan 14, 2025 | 10.4566 | 0.2900 | 2.85% | 10.1666 | 10.5866 | 9.9866 |
| Jan 13, 2025 | 9.9266 | -0.0200 | -0.20% | 9.9466 | 10.1166 | 9.4666 |
| Jan 10, 2025 | 9.9466 | 0.1300 | 1.32% | 9.8166 | 10.6566 | 9.7666 |
| Jan 8, 2025 | 9.5666 | -0.3500 | -3.53% | 9.9166 | 9.9666 | 9.5566 |
| Jan 7, 2025 | 9.9466 | 0.0300 | 0.30% | 9.9166 | 10.3166 | 9.9166 |
| Jan 6, 2025 | 9.6766 | -1.1900 | -10.95% | 10.8666 | 10.8866 | 9.6666 |
| Jan 3, 2025 | 10.7366 | -1.2300 | -10.28% | 11.9666 | 12.2166 | 10.6866 |
| Jan 2, 2025 | 11.9566 | -0.2100 | -1.73% | 12.1666 | 12.8566 | 11.9566 |
| Dec 31, 2024 | 12.0366 | -0.6500 | -5.12% | 12.6866 | 12.7666 | 11.9766 |
| Dec 30, 2024 | 12.6166 | 0.2500 | 2.02% | 12.3666 | 12.7666 | 11.9966 |
| Dec 27, 2024 | 12.4166 | -1.0500 | -7.80% | 13.4666 | 14.3566 | 12.3566 |
| Dec 26, 2024 | 13.0366 | 1.0400 | 8.67% | 11.9966 | 13.1366 | 11.8766 |
| Dec 24, 2024 | 11.8266 | -0.3400 | -2.79% | 12.1666 | 12.2166 | 11.7266 |
| Dec 23, 2024 | 12.1566 | 0.6400 | 5.56% | 11.5166 | 12.4966 | 11.2666 |
| Dec 20, 2024 | 11.0766 | 0.5600 | 5.32% | 10.5166 | 11.0866 | 10.3066 |
| Dec 19, 2024 | 10.6166 | -0.1500 | -1.39% | 10.7666 | 11.4666 | 10.5266 |
| Dec 18, 2024 | 10.6766 | -1.2900 | -10.78% | 11.9666 | 12.5766 | 10.5566 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Catalyst Biosciences, Inc. Company profile
About Catalyst Biosciences Inc
Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Catalyst Biosciences Inc revenues decreased 74% to $4.9M. Net loss increased 81% to $67.6M. Revenues reflect License decrease from $15.1M to $0K. Higher net loss reflects Research and development increase of 3% to $38.3M (expense), General and administrative - Balancing v increase of 9% to $11.3M (expense), Miscellaneous income (expense) decrease of 99% to $8K (income).
Equity composition
Common Stock $.001 Par, 04/11, 100M auth., 29,021,460 issd., Insiders control approx. 0.08%. IPO: 4/06 5,000,000 shs. @ $9per share by Deutsche Bank Securities. 8/15, 1-for-7 reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
12770 High Bluff Drive, Suite 150
SAN DIEGO
CALIFORNIA 92130
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com